Bradanicline

Drug Profile

Bradanicline

Alternative Names: ATA 101; TC-0569; TC-5619; TC-5619-238

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Targacept
  • Developer Attenua; Targacept
  • Class Amides; Azabicyclo compounds; Benzofurans; Nootropics; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cough
  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders

Most Recent Events

  • 11 Sep 2017 Preclinical trials in Cough in USA (PO)
  • 11 Sep 2017 Attenua plans a Proof of Concept trial for Cough in mid-2018
  • 02 Aug 2016 Catalyst Biosciences enters into a definitive agreement with Attenua for the divestiture of its neuronal nicotinic receptors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top